Safety and Efficacy of Post Ablation Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation

Trial Profile

Safety and Efficacy of Post Ablation Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Apixaban (Primary) ; Aspirin
  • Indications Stroke
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 05 Jan 2017 Planned End Date changed from 1 Dec 2018 to 1 Apr 2019.
    • 05 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top